

Comprehensive bibliography on Hypertrophic Cardiomyopathy including relevant, supplementary references to the ACC/ESC Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

Prepared by the ACC/ESC Committee to Develop a Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy—Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED

(References are listed in alphabetical order)

1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. *N Engl J Med* 1997;337:1576-83.
2. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. *J Am Coll Cardiol* 2002;39:2042-8.
3. Adabag AS, Casey SA, Maron BJ. Sudden death in hypertrophic cardiomyopathy: patterns and prognostic significance of tachyarrhythmias on ambulatory Holter ECG. *Circulation* 2002;106:II-710.
4. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. *Br Heart J* 1970;32:804-11.
5. Adelman AG, Wigle ED, Ranganathan N, et al. The clinical course in muscular subaortic stenosis: a retrospective and prospective study of 60 hemodynamically proved cases. *Ann Intern Med* 1972;77:515-25.
6. Agnew TM, Barratt-Boyes BG, Brandt PW, Roche AH, Lowe JB, O'Brien KP. Surgical resection in idiopathic hypertrophic subaortic stenosis with a combined approach through aorta and left ventricle. *J Thorac Cardiovasc Surg* 1977;74:307-16.
7. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. *J Clin Invest* 1994;93:280-5.
8. Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. *Circulation* 1998;98:391-7.
9. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. *J Clin Invest* 2002;109:357-62.
10. Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;40:1864-9.
11. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. *Hum Pathol* 2000;31:988-98.
12. Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H. Fabry disease in patients with hypertrophic cardiomyopathy (HCM). *Z Kardiol* 2002;91:992-1002.
13. Betocchi S, Hess OM, Losi MA, Nonogi H, Krayenbuehl HP. Regional left ventricular mechanics in hypertrophic cardiomyopathy. *Circulation* 1993;88:2206-14.
14. Betocchi S, Losi MA, Piscione F, et al. Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. *Am J Cardiol* 1996;77:498-502.
15. Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. *Hum Mol Genet* 2001;10:1215-20.
16. Boekstegers P, Steinbigler P, Molnar A, et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic

- obstructive cardiomyopathy. *J Am Coll Cardiol* 2001;38:846-53.
17. Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. *Am J Cardiol* 1983;51:1386-91.
 18. Bonow RO, Ostrow HG, Rosing DR, et al. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. *Circulation* 1983;68:1062-73.
 19. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. *Circulation* 1985;72:853-64.
 20. Bonow RO, Vitale DF, Maron BJ, Bacharach SL, Frederick TM, Green MV. Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. *J Am Coll Cardiol* 1987;9:1108-16.
 21. Boriani G, Rapezzi C, Biffi M, Branzi A, Spirito P. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol* 2002;13:954.
 22. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. *BMJ* 2002;324:699.
 23. Braunwald E, Lambrew C, Rockoff D, et al. Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. *Circulation* 1964;30 Suppl IV:3-217.
 24. Briguori C, Betocchi S, Losi MA, et al. Noninvasive evaluation of left ventricular diastolic function in hypertrophic cardiomyopathy. *Am J Cardiol* 1998;81:180-7.
 25. Briguori C, Betocchi S, Romano M, et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. *Am J Cardiol* 1999;84:309-15.
 26. Brock RC. Functional obstruction of the left ventricle. *Guy's Hosp Rep* 1957;106:221-38.
 27. Brugada R, Kelsey W, Lechin M, et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. *J Investig Med* 1997;45:542-51.
 28. Bryce M, Spielman SR, Greenspan AM, Kotler MN. Evolving indications for permanent pacemakers. *Ann Intern Med* 2001;134:1130-41.
 29. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 1999;341:1882-90.
 30. Camm AJ, Nisam S. The utilization of the implantable defibrillator—a European enigma. *Eur Heart J* 2000;21:1998-2004.
 31. Cannan CR, Reeder GS, Bailey KR, Melton LJ, III, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. *Circulation* 1995;92:2488-95.
 32. Cannon RO, III, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. *Circulation* 1985;71:234-43.
 33. Cannon RO, III, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1987;10:53-62.
 34. Cannon RO, III, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. *Circulation* 1989;79:766-75.
 35. Cannon RO, III, Tripodi D, Dilsizian V, Panza JA, Fananapazir L. Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. *Am J Cardiol* 1994;73:571-6.
 36. Cape EG, Simons D, Jimoh A, Weyman AE, Yoganathan AP, Levine RA. Chordal geometry determines the shape and extent of systolic anterior

- mitral motion: in vitro studies. *J Am Coll Cardiol* 1989;13:1438-48.
37. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. *J Am Coll Cardiol* 1989;13:1283-8.
 38. Cecchi F, Olivotto I, Monteregeggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. *J Am Coll Cardiol* 1995;26:1529-36.
 39. Cecchi F, Olivotto I, Monteregeggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. *Heart* 1998;79:331-6.
 40. Cecchi F, Olivotto I. New concepts in hypertrophic cardiomyopathies (correspondence). *Circulation* 2001;105:188e.
 41. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. *N Engl J Med*. In press.
 42. Charron P, Dubourg O, Desnos M, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. *Circulation* 1997;96:214-9.
 43. Charron P, Dubourg O, Desnos M, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. *Eur Heart J* 1998;19:1377-82.
 44. Charron P, Dubourg O, Desnos M, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. *Circulation* 1998;97:2230-6.
 45. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;40:2156-64.
 46. Ciampi Q, Betocchi S, Lombardi R, et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;40:278-84.
 47. Ciro E, Nichols PF, III, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy: two-dimensional echocardiographic analysis. *Circulation* 1983;67:1227-33.
 48. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. *Circulation* 1967;35:847-51.
 49. Cohn LH, Trehan H, Collins JJ, Jr. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. *Am J Cardiol* 1992;70:657-60.
 50. Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis: results in 27 patients. *J Cardiovasc Surg (Torino)* 1976;17:380-7.
 51. Cooley DA. Surgical techniques for hypertrophic left ventricular obstructive myopathy including mitral valve plication. *J Cardiovasc Surg* 1991;6:29-33.
 52. Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. *N Engl J Med* 2002;346:2062-8.
 53. Cooper MM, McIntosh CL, Tucker E, Clark RE. Operation for hypertrophic subaortic stenosis in the aged. *Ann Thorac Surg* 1987;44:370-8.
 54. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. *N Engl J Med* 1998;339:364-9.
 55. Corrado D, Basso C, Rizzoli G, Thiene G. Does sport activity enhance the risk of sudden death in adolescents and young adults? [abstr]. *Circulation* 2001;104 Suppl II:II-346.
 56. Coviello DA, Maron BJ, Spirito P, et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. *J Am Coll Cardiol* 1997;29:635-40.

57. Criley JM, Siegel RJ. Has 'obstruction' hindered our understanding of hypertrophic cardiomyopathy? *Circulation* 1985;72:1148-54.
58. Criley JM, Siegel RJ. Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy. *Postgrad Med J* 1986;62:515-29.
59. Criley JM. Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1997;29:741-3.
60. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. *Circulation* 1997;96:358-66.
61. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy—pathology and pathogenesis. *Histopathology* 1995;26:493-500.
62. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1993;22:796-804.
63. Diodati JG, Schenke WH, Waclawiw MA, McIntosh CL, Cannon RO, III. Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathy. *Am J Cardiol* 1992;69:1617-22.
64. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1999;33:1596-601.
65. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. *J Am Coll Cardiol* 2000;36:2212-8.
66. Elliott PM, Gimeno B, Jr., Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. *Lancet* 2001;357:420-4.
67. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. *Circulation* 1981;64:437-41.
68. Erdmann J, Raible J, Maki-Abadi J, et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2001;38:322-30.
69. Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;39:638-45.
70. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. *Circulation* 1998;98:2415-21.
71. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. *J Am Soc Echocardiogr* 2000;13:1074-9.
72. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. *Heart* 2000;83:326-31.
73. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1991;17:1343-51.
74. Falicov RE, Resnekov L, Bharati S, Lev M. Mid-ventricular obstruction: a variant of obstructive cardiomyopathy. *Am J Cardiol* 1976;37:432-7.
75. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy: a consecutive analysis in 155 patients. *Circulation* 1989;80:1259-68.
76. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. *Circulation* 1992;86:730-40.
77. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-

- chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. *Circulation* 1994;90:2731-42.
78. Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. *J Am Coll Cardiol* 1990;16:821-6.
79. Ferrans VJ, Morrow AG, Roberts WC. Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis: a study of operatively excised left ventricular outflow tract muscle in 14 patients. *Circulation* 1972;45:769-92.
80. Fiddler GI, Tajik AJ, Weidman W, McGoon DC, Ritter DG, Giuliani ER. Idiopathic hypertrophic subaortic stenosis in the young. *Am J Cardiol* 1978;42:793-9.
81. Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcatheter septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, hemodynamic and exercise outcomes. *Eur Heart J* 2002;20:1617-24.
82. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis: prevention of outflow obstruction with propranolol. *Circulation* 1968;38:846-58.
83. Flavigny J, Richard P, Isnard R et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. *J Mol Med* 1998;76:208-14.
84. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH, III, Nagueh SF. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 2001;37:208-14.
85. Fox PR, Liu SK, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy: an animal model of human disease. *Circulation* 1995;92:2645-51.
86. Frank MJ, Abdulla AM, Canedo MI, Saylor RE. Long-term medical management of hypertrophic obstructive cardiomyopathy. *Am J Cardiol* 1978;42:993-1001.
87. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. *Circulation* 1968;37:759-88.
88. Frenneaux MP, Porter A, Caforio AL, Odawara H, Counihan PJ, McKenna WJ. Determinants of exercise capacity in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1989;13:1521-6.
89. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. *Circulation* 1990;82:1995-2002.
90. Fujino N, Shimizu M, Ino H, et al. A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. *Am J Cardiol* 2002;89:29-33.
91. Fujiwara H, Kawai C, Hamashima Y. Myocardial fascicle and fiber disarray in 25 μ -thick sections. *Circulation* 1979;59:1293-8.
92. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. *Eur Heart J* 2001;22:1852-923.
93. Gadler F, Linde C, Juhlin-Dannfelt A, Ribeiro A, Ryden L. Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. *Eur Heart J* 1997;18:636-42.
94. Gadler F, Linde C, Daubert C, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy: data from 1 year of follow-up. PIC study group. *Pacing In Cardiomyopathy. Eur Heart J* 1999;20:1044-50.
95. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. *Cell* 1990;62:999-1006.

96. Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. *Science* 1996;272:731-4.
97. Gidding SS, Snider AR, Rocchini AP, Peters J, Farnsworth R. Left ventricular diastolic filling in children with hypertrophic cardiomyopathy: assessment with pulsed Doppler echocardiography. *J Am Coll Cardiol* 1986;8:310-6.
98. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcatheter ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. *Eur Heart J* 1999;20:1342-54.
99. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Muller C, Kuhn H. Role of transcatheter ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, NYHA functional class III or IV and outflow obstruction only under provokable conditions. *Circulation* 2002;106:454-9.
100. Gilligan DM, Chan WL, Ang EL, Oakley CM. Effects of a meal on hemodynamic function at rest and during exercise in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1991;18:429-36.
101. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1993;21:1672-9.
102. Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. *Am J Cardiol* 1994;74:363-8.
103. Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. *Br Heart J* 1970;32:652-9.
104. Glancy DL, Shepherd RL, Beiser D, Epstein SE. The dynamic nature of left ventricular outflow obstruction in idiopathic hypertrophic subaortic stenosis. *Ann Intern Med* 1971;75:589-93.
105. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. *N Engl J Med* 2001;344:1823-31.
106. Goodwin JF. The frontiers of cardiomyopathy. *Br Heart J* 1982;48:1-18.
107. Gras D, Lequercq C, De Place C, et al. The potential role of dual-chamber pacing in the management of elderly patients with hypertrophic cardiomyopathy. *Cardiology in the Elderly* 1995;26:430-8.
108. Greenspan AM. Hypertrophic cardiomyopathy and atrial fibrillation: a change of perspective. *J Am Coll Cardiol* 1990;15:1286-7.
109. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). *Circulation* 2002;106:2145-61.
110. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. *J Am Coll Cardiol* 1992;20:42-52.
111. Grover-McKay M, Schwaiger M, Krivokapich J, Perloff JK, Phelps ME, Schelbert HR. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1989;13:317-24.
112. Gruver EJ, Fatkin D, Dodds GA, et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. *Am J Cardiol* 1999;83:13H-8H.
113. Hagege AA, Dubourg O, Desnos M, et al. Familial hypertrophic cardiomyopathy: cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. *Eur Heart J* 1998;19:490-9.
114. Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. *Am J Cardiol* 1980;45:1258-64.
115. Hanrath P, Mathey D, Montz R, et al. Myocardial thallium 201 imaging in hypertrophic obstructive cardiomyopathy. *Eur Heart J* 1981;2:177-85.

116. Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. *Lancet* 1973;2:1462-7.
117. Hecht GM, Panza JA, Maron BJ. Clinical course of middle-aged asymptomatic patients with hypertrophic cardiomyopathy. *Am J Cardiol* 1992;69:935-40.
118. Hecht GM, Klues HG, Roberts WC, Maron BJ. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1993;22:489-97.
119. Henein MY, O'Sullivan CA, Ramzy IS, Sigwart U, Gibson DG. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1999;34:1117-22.
120. Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. *Circulation* 1976;53:273-9.
121. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. *J Thorac Cardiovasc Surg* 1995;110:195-206.
122. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. *Circulation* 2000;102:1950-5.
123. Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. *Circulation* 2002;105:2997.
124. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. *Lancet* 1992;339:1318-23.
125. Jeanrenaud X, Schlapfer J, Fromer M, Aebischer N, Kappenberger L. Dual chamber pacing in hypertrophic obstructive cardiomyopathy: beneficial effect of atrioventricular junction ablation for optimal left ventricular capture and filling. *Pacing Clin Electrophysiol* 1997;20:293-300.
126. Jenni R, Oechslin E, Schneider J, Jost CA, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. *Heart* 2001;86:666-71.
127. Jiang L, Levine RA, King ME, Weyman AE. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. *Am Heart J* 1987;113:633-44.
128. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. *Br Heart J* 1979;42:35-42.
129. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy: a randomized crossover study. PIC Study Group. *Eur Heart J* 1997;18:1249-56.
130. Kappenberger LJ, Linde C, Jeanrenaud X, et al. Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group. *Europace* 1999;1:77-84.
131. Kim JJ, Lee CW, Park SW, et al. Improvement in exercise capacity and exercise blood pressure response after transcatheter alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. *Am J Cardiol* 1999;83:1220-3.
132. Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. *Nat Genet* 1997;16:379-82.
133. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. *Circulation* 1998;97:461-6.
134. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. *Circulation* 1991;84:1188-97.
135. Klues HG, Leuner C, Kuhn H. Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. *J Am Coll Cardiol* 1992;19:527-33.
136. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in

- hypertrophic cardiomyopathy. *Circulation* 1992;85:1651-60.
137. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. *Circulation* 1993;87:1570-9.
138. Klues HG, Schiffrers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. *J Am Coll Cardiol* 1995;26:1699-708.
139. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. *Circulation* 1997;95:2075-81.
140. Kofflard MJ, van Herwerden LA, Waldstein DJ, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1996;28:197-202.
141. Kofflard MJ, ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. *J Am Coll Cardiol* 2003;41:987-93.
142. Koga Y, Itaya K, Toshima H. Prognosis in hypertrophic cardiomyopathy. *Am Heart J* 1984;108:351-9.
143. Kokado H, Shimizu M, Yoshio H, et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. *Circulation* 2000;102:663-9.
144. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy: ten-year follow-up in 185 patients. *Circulation* 1989;80:I57-I64.
145. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. *Circulation* 1998;97:230-3.
146. Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. *Br Heart J* 1980;43:245-51.
147. Kuck KH, Kunze KP, Schluter M, Nienaber CA, Costard A. Programmed electrical stimulation in hypertrophic cardiomyopathy: results in patients with and without cardiac arrest or syncope. *Eur Heart J* 1988;9:177-85.
148. Kuhn H, Thelen U, Kohler E, Losse B. Hypertrophic non-obstructive cardiomyopathy (HNCM)—clinical, hemodynamic, electro-, echo- and angiocardigraphic studies. *Z Kardiol* 1980;69:457-69.
149. Kuhn H, Mercier J, Köhler E, Frenzel H, Hort W, Loogen F. Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic obstructive cardiomyopathy, atypical (mid-ventricular) hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy. *Eur Heart J* 1983;4 Suppl F:93-104.
150. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. *Eur Heart J* 1997;18:846-51.
151. Kuhn H, Gietzen FH, Schafers M, et al. Changes in the left ventricular outflow tract after transcatheter ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. *Eur Heart J* 1999;20:1808-17.
152. Kuhn H, Gietzen FH, Leuner C, et al. Transcatheter ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. *Z Kardiol* 2000;89 Suppl 4:IV41-54.
153. Kuhn H. Transcatheter ablation of septal hypertrophy (TASH): a 5-year experience. *Z Kardiol* 2000;89:559-64.
154. Kuhn H, Gietzen F, Leuner C. 'The abrupt no-flow': a no-reflow like phenomenon in hypertrophic cardiomyopathy. *Eur Heart J* 2002;23:91-3.

155. Kyriakidis M, Triposkiadis F, Anastasakis A, et al. Hypertrophic cardiomyopathy in Greece: clinical course and outcome. *Chest* 1998;114:1091-6.
156. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. *Circulation* 1998;98:1750-5.
157. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH, III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. *J Am Coll Cardiol* 2000;36:852-5.
158. Lechin M, Quinones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. *Circulation* 1995;92:1808-12.
159. Lele SS, Thomson HL, Seo H, Belenkie I, McKenna WJ, Frenneaux MP. Exercise capacity in hypertrophic cardiomyopathy: role of stroke volume limitation, heart rate, and diastolic filling characteristics. *Circulation* 1995;92:2886-94.
160. Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. *Circulation* 1989;79:580-9.
161. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. *J Am Coll Cardiol* 1989;13:36-45.
162. Lewis JF, Spirito P, Pelliccia A, Maron BJ. Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy. *Br Heart J* 1992;68:296-300.
163. Lewis JF, Maron BJ. Clinical and morphologic expression of hypertrophic cardiomyopathy in patients ≥ 65 years of age. *Am J Cardiol* 1994;73:1105-11.
164. Lim D, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. *J Am Coll Cardiol* 2001;38:1175-80.
165. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. *Circulation* 2001;103:789-91.
166. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. *Pacing In Cardiomyopathy. Am J Cardiol* 1999;83:903-7.
167. Loogen F, Kuhn H, Gietzen F, Losse B, Schulte HD, Bircks W. Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. *Eur Heart J* 1983;4 Suppl F:145-53.
168. Losi MA, Betocchi S, Grimaldi M, Spampinato N, Chiariello M. Heterogeneity of left ventricular filling dynamics in hypertrophic cardiomyopathy. *Am J Cardiol* 1994;73:987-90.
169. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. *J Am Coll Cardiol* 1986;8:57-65.
170. Louie EK, Maron BJ. Apical hypertrophic cardiomyopathy: clinical and two-dimensional echocardiographic assessment. *Ann Intern Med* 1987;106:663-70.
171. Louie EK, Edwards LC, III. Hypertrophic cardiomyopathy. *Prog Cardiovasc Dis* 1994;36:275-308.
172. Luria D, Klutstein MW, Rosenmann D, Shaheen J, Sergey S, Tzivoni D. Prevalence and significance of left ventricular outflow gradient during dobutamine echocardiography. *Eur Heart J* 1999;20:386-92.
173. Madariaga I, Carmona JR, Mateas FR, Lezaun R, de los AE. Supraventricular arrhythmia as the cause of sudden death in hypertrophic cardiomyopathy. *Eur Heart J* 1994;15:134-7.
174. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. *Am J Cardiol* 1998;82:774-8.
175. Manganelli F, Betocchi S, Ciampi Q, et al. Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope. *Am J Cardiol* 2002;89:1405-10.

176. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. *Lancet* 1993;342:1085-6.
177. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. *Circulation* 1995;92:1336-47.
178. Marian AJ, Wu Y, Lim DS, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. *J Clin Invest* 1999;104:1683-92.
179. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. *Lancet* 2000;355:58-60.
180. Maron BJ, Henry WL, Clark CE, Redwood DR, Roberts WC, Epstein SE. Asymmetric septal hypertrophy in childhood. *Circulation* 1976;53:9-19.
181. Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. *Circulation* 1978;57:1205-13.
182. Maron BJ, Roberts WC, Edwards JE, McAllister HA, Jr., Foley DD, Epstein SE. Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. *Am J Cardiol* 1978;41:803-10.
183. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. *Am J Cardiol* 1979;43:1242-4.
184. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. *Am J Cardiol* 1979;43:1086-102.
185. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. *Circulation* 1979;59:689-706.
186. Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE. Sudden death in young athletes. *Circulation* 1980;62:218-29.
187. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. *Circulation* 1981;63:882-94.
188. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. *Am J Cardiol* 1981;48:418-28.
189. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. *Am J Cardiol* 1981;48:252-7.
190. Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. *Circulation* 1982;65:7-17.
191. Maron BJ, Bonow RO, Seshagiri TN, Roberts WC, Epstein SE. Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). *Am J Cardiol* 1982;49:1838-48.
192. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. *Circulation* 1982;65:1388-94.
193. Maron BJ, Epstein SE, Morrow AG. Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. *Eur Heart J* 1983;4 Suppl F:175-85.
194. Maron BJ, Harding AM, Spirito P, Roberts WC, Waller BF. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. *Circulation* 1983;68:282-93.
195. Maron BJ, Nichols PF, III, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M- mode and two-dimensional echocardiography. *Am J Cardiol* 1984;53:1087-94.
196. Maron BJ, Epstein SE. Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. *Am J Cardiol* 1986;58:1093-6.

197. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1986;8:545-57.
198. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. *N Engl J Med* 1986;315:610-4.
199. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. *J Am Coll Cardiol* 1986;7:204-14.
200. Maron BJ, Bonow RO, Cannon RO, III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. *N Engl J Med* 1987;316:844-52.
201. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1987;10:733-42.
202. Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. *Br Heart J* 1990;63:308-10.
203. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. *Am J Cardiol* 1993;72:970-2.
204. Maron BJ, McIntosh CL, Klues HG, Cannon RO, III, Roberts WC. Morphologic basis for obstruction to right ventricular outflow in hypertrophic cardiomyopathy. *Am J Cardiol* 1993;71:1089-94.
205. Maron BJ, Hecht G, Klues HG, Kunkes SH, Rosenfeld LE, Cecchi F. Both aborted sudden cardiac death and end-stage phase in hypertrophic cardiomyopathy. *Am J Cardiol* 1993;72:363-5.
206. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. *J Am Coll Cardiol* 1994;24:880-5.
207. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. *Am J Cardiol* 1994;73:577-80.
208. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. *Am J Cardiol* 1994;73:1098-104.
209. Maron BJ, Kogan J, Proschan MA, Hecht GM, Roberts WC. Circadian variability in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1994;23:1405-9.
210. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. *Br Heart J* 1994;72:S13-S18.
211. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. *Circulation* 1995;92:785-9.
212. Maron BJ, Gross BW, Stark SI. Images in cardiovascular medicine: extreme left ventricular hypertrophy. *Circulation* 1995;92:2748.
213. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. *Circulation* 1995;91:1596-601.
214. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. *JAMA* 1996;276:199-204.
215. Maron BJ. Hypertrophic cardiomyopathy. *Lancet* 1997;350:127-33.
216. Maron BJ. Cardiovascular risks to young persons on the athletic field. *Ann Intern Med* 1998;129:379-86.
217. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. [A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic

- Science, American Heart Association]. *Circulation* 1998;98:1460-71.
218. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. *Circulation* 1998;98:2505-8.
219. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. *Am J Cardiol* 1998;81:1339-44.
220. Maron BJ, Casey SA, Gohman TE, Aeppli DM. Impact of gender on the clinical and morphologic expression of hypertrophic cardiomyopathy [abstr]. *Circulation* 1999;100:I-212.
221. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, crossover study (M-PATHY). *Circulation* 1999;99:2927-33.
222. Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. *J Am Coll Cardiol* 1999;33:1590-5.
223. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. *JAMA* 1999;281:650-5.
224. Maron BJ. New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. *Eur Heart J* 1999;20:1292-4.
225. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:365-73.
226. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. *Lancet* 2000;355:425-6.
227. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. *Circulation* 2000;102:858-64.
228. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. *J Am Coll Cardiol* 2001;38:315-21.
229. Maron BJ, Spirito P, Roman MJ, et al. Prevalence of hypertrophic cardiomyopathy in a general population-based sample of American Indians: the Strong Heart Study. *Circulation*. In press.
230. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. *JAMA* 2002;287:1308-20.
231. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;39:301-7.
232. Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2003;41:974-80.
233. Maron BJ, Estes NAM, III, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. *Circulation* 2003;107:2872-5.
234. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. *J Am Coll Cardiol*. In press.
235. Maron BJ, Piccininno M, Casey SA, Bernabo P, Spirito P. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. *Am J Cardiol* 2003;91:42.
236. Maron MS, Gohman TE, Casey SA, Maron BJ. Significance and relationship between magnitude of left ventricular hypertrophy and congestive heart failure symptoms in hypertrophic cardiomyopathy [abstr]. *J Am Coll Cardiol* 2002;39 Suppl A:173A.
237. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med* 2003;348:295-303.
238. Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1992;20:1066-72.

239. Matsubara H, Nakatani S, Nagata S, et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1995;26:768-75.
240. Matsuda H, Nomura F, Kadoba K, et al. Transatrial and transmitral approach for left ventricular myectomy and mitral valve plication for diffuse-type hypertrophic obstructive cardiomyopathy: a novel approach. *J Thorac Cardiovasc Surg* 1996;112:195-6.
241. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. *Circulation* 2001;103:1492-6.
242. McCully RB, Nishimura RA, Bailey KR, Schaff HV, Danielson GK, Tajik AJ. Hypertrophic obstructive cardiomyopathy: preoperative echocardiographic predictors of outcome after septal myectomy. *J Am Coll Cardiol* 1996;27:1491-6.
243. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. *Circulation* 1996;94:467-71.
244. McDonald K, McWilliams E, O'Keefe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. *Eur Heart J* 1988;9:893-8.
245. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. *Circulation* 1988;78:487-95.
246. McIntosh CL, Greenberg GJ, Maron BJ, Leon MB, Cannon RO, III, Clark RE. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. *Ann Thorac Surg* 1989;47:236-46.
247. McIntosh CL, Maron BJ, Cannon RO, III, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. *Circulation* 1992;86:II60-II67.
248. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. *Am J Cardiol* 1981;47:532-8.
249. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: influence on prognosis. *Br Heart J* 1981;46:168-72.
250. McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. *Am J Cardiol* 1984;54:802-10.
251. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. *Arch Dis Child* 1984;59:971-5.
252. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. *Br Heart J* 1985;53:412-6.
253. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1988;11:147-53.
254. Meisel E, Rauwolf T, Burghardt M, Kappenberger L. Pacemaker therapy of hypertrophic obstructive cardiomyopathy. PIC (Pacing in Cardiomyopathy) Study Group. *Herz* 2000;25:461-6.
255. Merrill WH, Friesinger GC, Graham TP, Jr., et al. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy. *Ann Thorac Surg* 2000;69:1732-5.
256. Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. *J Clin Invest* 1999;103:R39-R43.
257. Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. *J Clin Invest* 2003;111:209-16.
258. Mohr R, Schaff HV, Puga FJ, Danielson GK. Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age. *Circulation* 1989;80:1191-1196.
259. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, Tajik AJ. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: experience over 15 years. *J Thorac Cardiovasc Surg* 1989;97:666-74.

260. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. *J Am Coll Cardiol*. In press.
261. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. *J Am Coll Cardiol* 1997;29:549-55.
262. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. *J Am Coll Cardiol* 2003;41:1561-7.
263. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre- and postoperative assessments in 83 patients. *Circulation* 1975;52:88-102.
264. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;335:1933-40.
265. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;346:877-83.
266. Murgo JP, Alter BR, Dorethy JF, Altobelli SA, McGranahan GM, Jr. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. *J Clin Invest* 1980;66:1369-82.
267. Muthuchamy M, Pieples K, Rethinasamy P, et al. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. *Circ Res* 1999;85:47-56.
268. Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1998;32:225-9.
269. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. *Circulation* 1999;99:344-7.
270. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1999;34:1123-8.
271. Nagueh SF, Stetson SJ, Lakkis NM, et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. *Circulation* 2001;103:1844-50.
272. Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. *Circulation* 2001;104:128-30.
273. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 2001;38:1701-6.
274. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. *N Engl J Med* 1988;318:1255-7.
275. Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. *Circulation* 1993;87:1580-90.
276. Nihoyannopoulos P, Karatasakis G, Frenneaux M, McKenna WJ, Oakley CM. Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. *J Am Coll Cardiol* 1992;19:536-40.
277. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. *N Engl J Med* 1998;338:1248-57.
278. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. *Circulation* 2002;105:446-51.

279. Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR, Jr., Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. *J Am Coll Cardiol* 1996;27:421-30.
280. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. *J Am Coll Cardiol* 1997;29:435-41.
281. O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. *Circulation* 1987;76:1214-23.
282. Obeid AI, Maron BJ. Apical hypertrophic cardiomyopathy developing at a relatively advanced age. *Circulation* 2001;103:1605.
283. Oberst L, Zhao G, Park JT, et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. *J Clin Invest* 1998;102:1498-505.
284. Okeie K, Shimizu M, Yoshio H, et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2000;36:856-63.
285. Olivotto I, Maron BJ, Monterege A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1999;33:2044-51.
286. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation* 2001;104:2517-24.
287. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. *J Am Coll Cardiol* 1999;34:191-6.
288. Ommen SR, Thomson HL, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Clinical predictors and consequences of atrial fibrillation after surgical myectomy for obstructive hypertrophic cardiomyopathy. *Am J Cardiol* 2002;89:242-4.
289. Osterop AP, Kofflard MJ, Sandkuijl LA, et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. *Hypertension* 1998;32:825-30.
290. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. *J Am Coll Cardiol* 1999;34:1813-22.
291. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344:1651-8.
292. Palka P, Lange A, Fleming AD, et al. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. *J Am Coll Cardiol* 1997;30:760-8.
293. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. *Am J Cardiol* 1989;63:1258-65.
294. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1992;19:91-9.
295. Panza JA, Maris TJ, Maron BJ. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. *Circulation* 1992;85:1398-405.
296. Pasternac A, Noble J, Streulens Y, Elie R, Henschke C, Bourassa MG. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. *Circulation* 1982;65:778-89.
297. Pavin D, de Place C, Le Breton H, et al. Effects of permanent dual-chamber pacing on mitral regurgitation in hypertrophic obstructive cardiomyopathy. *Eur Heart J* 1999;20:203-10.

298. Paz R, Jortner R, Tunick PA, et al. The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy. *N Engl J Med* 1996;335:938-41.
299. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. *N Engl J Med* 1991;324:295-301.
300. Pellicka PA, Oh JK, Bailey KR, Nichols BA, Monahan KH, Tajik AJ. Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation. *Circulation* 1992;86:1429-32.
301. Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurea S, Bonow RO. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. *Am J Cardiol* 1993;72:199-204.
302. Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. *J Am Coll Cardiol* 1992;20:55-61.
303. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. *Nat Genet* 1996;13:63-9.
304. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. *N Engl J Med* 1982;307:997-9.
305. Pollick C, Morgan CD, Gilbert BW, Rakowski H, Wigle ED. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. *Circulation* 1982;66:1087-94.
306. Pollick C, Rakowski H, Wigle ED. Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. *Circulation* 1984;69:43-9.
307. Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy: I: hemodynamic assessment after intravenous administration. *Am J Cardiol* 1988;62:1248-51.
308. Pasma JL, Blanksma PK, Van Der Wall EE, Vaalburg W, Crijns HJ, Lie KI. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. *Heart* 1996;76:358-62.
309. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. *Eur Heart J* 2001;22:1374-450.
310. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. *J Am Coll Cardiol* 2001;38:1994-2000.
311. Qin JX, Shiota T, Lever HM, et al. Impact of left ventricular outflow tract area on systolic outflow velocity in hypertrophic cardiomyopathy: a real-time three-dimensional echocardiographic study. *J Am Coll Cardiol* 2002;39:308-14.
312. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. *Cardiovasc Res* 1999;44:20-36.
313. Redwood DR, Goldstein RE, Hirshfeld J, et al. Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy. *Am J Cardiol* 1979;44:215-20.
314. Rickers C, Wilkie NM, Casey S, et al. Identification of hypertrophic cardiomyopathy by magnetic resonance imaging in the absence of echocardiographic diagnosis [abstr]. *Circulation* 2002;106.
315. Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1997;29:734-40.
316. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. *J Thorac Cardiovasc Surg* 1996;111:586-94.
317. Roberts WC. Operative treatment of hypertrophic obstructive cardiomyopathy. The case against mitral valve replacement. *Am J Cardiol* 1973;32:377-81.
318. Roberts WC, Kishel JC, McIntosh CL, Cannon RO, III, Maron BJ. Severe mitral or aortic valve regurgitation, or both, requiring valve replacement

- for infective endocarditis complicating hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1992;19:365-71.
319. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. *J Am Coll Cardiol* 1990;15:1279-85.
320. Romeo F, Pelliccia F, Cristofani R, Martuscelli E, Reale A. Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant? *Eur Heart J* 1990;11:233-40.
321. Rosenzweig A, Watkins H, Hwang DS *et al.* Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. *N Engl J Med* 1991;325:1753-60.
322. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: II: effects on exercise capacity and symptomatic status. *Circulation* 1979;60:1208-13.
323. Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. *Circulation* 1979;60:1201-7.
324. Rosing DR, Condit JR, Maron BJ, *et al.* Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III: effects of long-term administration. *Am J Cardiol* 1981;48:545-53.
325. Ross J, Jr., Braunwald E, Gault JH, Mason DT, Morrow AG. The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. *Circulation* 1966;34:558-78.
326. Ruzyllo W, Chojnowska L, Demkow M, *et al.* Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. *Eur Heart J* 2000;21:770-7.
327. Sachdev B, Takenaka T, Teraguchi H, *et al.* Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. *Circulation* 2002;105:1407-11.
328. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. *Circulation* 1997;96:2987-91.
329. Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. *Jpn Heart J* 1976;17:611-29.
330. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1988;11:752-6.
331. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. *Biochem Biophys Res Commun* 1999;262:411-7.
332. Saumarez RC, Slade AK, Grace AA, Sadoul N, Camm AJ, McKenna WJ. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy: a prospective study. *Circulation* 1995;91:2762-8.
333. Schaffer MS, Freedom RM, Rowe RD. Hypertrophic cardiomyopathy presenting before 2 years of age in 13 patients. *Pediatr Cardiol* 1983;4:113-9.
334. Schapira JN, Stemple DR, Martin RP, Rakowski H, Stinson EB, Popp RL. Single and two-dimensional echocardiographic visualization of the effects of septal myectomy in idiopathic hypertrophic subaortic stenosis. *Circulation* 1978;58:850-60.
335. Schoendube FA, Klues HG, Reith S, Messmer BJ. Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles. *Eur J Cardiothorac Surg* 1994;8:603-8.
336. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. *Circulation* 1995;92:II122-II127.
337. Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B. Prognosis of patients with hypertrophic obstructive cardiomyopathy after

- transaortic myectomy: late results up to twenty-five years. *J Thorac Cardiovasc Surg* 1993;106:709-17.
338. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy—long-term results after surgical therapy. *Thorac Cardiovasc Surg* 1999;47:213-8.
339. Schwammenthal E, Block M, Schwartzkopff B, et al. Prediction of the site and severity of obstruction in hypertrophic cardiomyopathy by color flow mapping and continuous wave Doppler echocardiography. *J Am Coll Cardiol* 1992;20:964-72.
340. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. *Circulation* 1995;91:532-40.
341. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. *J Am Coll Cardiol* 1998;31:1089-96.
342. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. *J Am Coll Cardiol* 1998;31:252-8.
343. Seggewiss H, Faber L, Ziemssen P. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. *Cardiol Rev* 1999;7:316-23.
344. Seidman JG, Seidman CE. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. *Cell* 2001;104:557-67.
345. Semsarian C, French J, Trent RJ, Richmond DR, Jeremy RW. The natural history of left ventricular wall thickening in hypertrophic cardiomyopathy. *Aust N Z J Med* 1997;27:51-8.
346. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. *J Clin Invest* 2002;109:1013-20.
347. Shah PM, Gramiak R, Kramer DH. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. *Circulation* 1969;40:3-11.
348. Shah PM, Gramiak R, Adelman AG, Wigle ED. Echocardiographic assessment of the effects of surgery and propranolol on the dynamics of outflow obstruction in hypertrophic subaortic stenosis. *Circulation* 1972;45:516-21.
349. Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. *Circ Res* 1974;35 Suppl II:179-95.
350. Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. *Am J Cardiol* 1981;48:258-62.
351. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. *J Am Coll Cardiol* 1983;2:437-44.
352. Shapiro LM, Zezulka A. Hypertrophic cardiomyopathy: a common disease with a good prognosis: five year experience of a district general hospital. *Br Heart J* 1983;50:530-3.
353. Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. *Am J Cardiol* 2000;86:162-8.
354. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. *Am J Cardiol* 1988;62:1085-8.
355. Sherrid MV, Chu CK, Delia E, Mogtader A, Dwyer EM, Jr. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1993;22:816-25.
356. Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. *Circulation* 1998;97:41-7.
357. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2000;36:1344-54.
358. Shirani J, Maron BJ, Cannon RO, III, Shahin S, Roberts WC. Clinicopathologic features of

- hypertrophic cardiomyopathy managed by cardiac transplantation. *Am J Cardiol* 1993;72:434-40.
359. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. *J Am Coll Cardiol* 2000;35:36-44.
360. Siegel RJ, Criley JM. Comparison of ventricular emptying with and without a pressure gradient in patients with hypertrophic cardiomyopathy. *Br Heart J* 1985;53:283-91.
361. Siegman IL, Maron BJ, Permut LC, McIntosh CL, Clark RE. Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease. *J Am Coll Cardiol* 1989;13:1527-33.
362. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. *Lancet* 1995;346:211-4.
363. Silka MJ, Kron J, Dunnigan A, Dick M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. *Circulation* 1993;87:800-7.
364. Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. *Heart* 1997;77:229-33.
365. Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. *Heart* 1996;75:44-9.
366. Sloman G. Propranolol in management of muscular subaortic stenosis. *Br Heart J* 1967;29:783-7.
367. Solomon SD, Wolff S, Watkins H, et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. *J Am Coll Cardiol* 1993;22:498-505.
368. Speiser KW, Krayenbuehl HP. Reappraisal of the effect of acute beta-blockade on left ventricular filling dynamics in hypertrophic obstructive cardiomyopathy. *Eur Heart J* 1981;2:21-9.
369. Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. *Am J Cardiol* 1984;53:1614-9.
370. Spirito P, Maron BJ. Significance of left ventricular outflow tract cross-sectional area in hypertrophic cardiomyopathy: a two-dimensional echocardiographic assessment. *Circulation* 1983;67:1100-8.
371. Spirito P, Maron BJ, Rosing DR. Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M mode and two-dimensional echocardiographic assessment. *Circulation* 1984;70:984-95.
372. Spirito P, Maron BJ. Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography. *Am J Cardiol* 1984;54:1039-46.
373. Spirito P, Maron BJ, Chiarella F, et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. *Circulation* 1985;72:310-6.
374. Spirito P, Maron BJ, Bonow RO, Epstein SE. Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy. *J Am Coll Cardiol* 1986;8:537-44.
375. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. *Am J Cardiol* 1987;60:123-9.
376. Spirito P, Watson RM, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. *Am J Cardiol* 1987;60:1137-42.
377. Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1987;9:1013-7.
378. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. *N Engl J Med* 1989;320:749-55.

379. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1990;15:808-13.
380. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1990;15:1521-6.
381. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. *Am J Cardiol* 1992;69:1217-22.
382. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. *Circulation* 1994;90:2743-7.
383. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. *N Engl J Med* 1997;336:775-85.
384. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1999;33:1071-5.
385. Spirito P, Rapezzi C, Bellone P, et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. *Circulation* 1999;99:2132-7.
386. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:1778-85.
387. St.John Sutton MG, Lie JT, Anderson KR, O'Brien PC, Frye RL. Histopathological specificity of hypertrophic obstructive cardiomyopathy: myocardial fibre disarray and myocardial fibrosis. *Br Heart J* 1980;44:433-43.
388. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1986;7:701-4.
389. Stenson RE, Flamm MD, Jr., Harrison DC, Hancock EW. Hypertrophic subaortic stenosis: clinical and hemodynamic effects of long-term propranolol therapy. *Am J Cardiol* 1973;31:763-73.
390. Sutton MG, Tajik AJ, Gibson DG, Brown DJ, Seward JB, Guiliani ER. Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis. *Circulation* 1978;57:512-20.
391. Swan DA, Bell B, Oakley CM, Goodwin J. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. *Br Heart J* 1971;33:671-85.
392. Swanton RH, Brooksby IA, Jenkins BS, Webb-Peploe MM. Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy. *Eur J Cardiol* 1977;5:327-41.
393. Sweeney HL, Feng HS, Yang Z, Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. *Proc Natl Acad Sci U S A* 1998;95:14406-10.
394. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1999;33:206-11.
395. Takata J, Counihan PJ, Gane JN, et al. Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain. *Am J Cardiol* 1993;72:211-7.
396. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. *Br Heart J* 1986;55:575-81.
397. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. *Circulation* 1987;75:1130-9.
398. Tardiff JC, Factor SM, Tompkins BD, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. *J Clin Invest* 1998;101:2800-11.
399. Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br Heart J* 1958;20:1-18.
400. ten Berg JM, Suttorp MJ, Knaepen PJ, Ernst SM, Vermeulen FE, Jaarsma W. Hypertrophic obstructive

- cardiomyopathy: initial results and long-term follow-up after Morrow septal myectomy. *Circulation* 1994;90:1781-5.
401. ten Cate FJ, Roelandt J. Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. *Am Heart J* 1979;97:762-5.
402. Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. *J Thorac Cardiovasc Surg* 1996;112:1589-97.
403. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. *Cell* 1994;77:701-12.
404. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. *Circulation* 1989;79:1052-60.
405. Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. *Circulation* 2002;106:3085-90.
406. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. *Circulation* 2001;104:1380-4.
407. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. *Am J Cardiol* 2001;88:275-9.
408. Vikstrom KL, Factor SM, Leinwand LA. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. *Mol Med* 1996;2:556-67.
409. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. *N Engl J Med* 1992;326:1108-14.
410. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. *J Clin Invest* 1992;90:1666-71.
411. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med* 1995;332:1058-64.
412. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. *Nat Genet* 1995;11:434-7.
413. Watkins H. Sudden death in hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:422-4.
414. Webb JG, Sasson Z, Rakowski H, Liu P, Wigle ED. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. *J Am Coll Cardiol* 1990;15:83-90.
415. Wigle E.D., Heimbecker RO, Gunton RW. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. *Circulation* 1962;26:325-40.
416. Wigle ED, Marquis Y, Auger P. Muscular subaortic stenosis: initial left ventricular inflow tract pressure in the assessment of intra-ventricular pressure differences in man. *Circulation* 1967;35:1100-17.
417. Wigle ED, Adelman AG, Auger P, Marquis Y. Mitral regurgitation in muscular subaortic stenosis. *Am J Cardiol* 1969;24:698-706.
418. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy. A review. *Prog Cardiovasc Dis* 1985;28:1-83.
419. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. *Circulation* 1995;92:1680-92.
420. Wigle ED. Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. *Heart* 2001;86:709-14.
421. Wigle ED, Schwartz L, Woo A, Rakowski H. To ablate or operate? That is the question (editorial). *J Am Coll Cardiol* 2001;15:1707-10.
422. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. *Circulation* 1987;76:V104-V108.

423. Wilson WS, Criley JM, Ross RS. Dynamics of left ventricular emptying in hypertrophic subaortic stenosis: a cineangiographic and hemodynamic study. *Am Heart J* 1967;73:4-16.
424. Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. *Am J Cardiol* 1979;44:401-12.
425. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. *J Clin Invest* 1998;102:1292-300.
426. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. *N Engl J Med* 1998;339:1201-9.
427. Yu B, French JA, Carrier L, et al. Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. *J Med Genet* 1998;35:205-10.
428. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. *J Am Coll Cardiol* 2000;36:2219-25.